Hydrashift 2/4 daratumumab检测消除达雷妥尤单抗对血清免疫固定电泳干扰的应用  

Application of Hydrashift 2/4 daratumumab assay in eliminating interference of daratumumab on serum immunofixation electrophoresis

作　　者：徐双[1] 刘扬[2] 温磊[2] 赵磊[1] 邓旭[1] 荣嵘[1] 路瑾[2,3] Xu Shuang;Liu Yang;Wen Lei;Zhao Lei;Deng Xu;Rong Rong;Lu Jin(Department of Clinical Laboratory,Peking University People's Hospital,Beijing 100044,China;Department of Hematology,Peking University People's Hospital,Peking University Institute of Hematology,National Clinical Research Center for Hematologic Disease,Beijing 100044,China;Center for Collaborative Innovation in Hematology,Suzhou 215006,China)

机构地区：[1]北京大学人民医院检验科,北京100044 [2]北京大学人民医院血液科,北京大学血液病研究所,国家血液系统疾病临床医学研究中心,北京100044 [3]血液学协同创新中心,苏州215006

出　　处：《中华血液学杂志》2021年第10期840-845,共6页Chinese Journal of Hematology

基　　金：首都卫生发展科研专项资助项目(2020-2-4-82);北京大学人民医院研究与发展基金资助项目(RDE2020-15)。

摘　　要：目的探讨达雷妥尤单抗治疗浆细胞疾病后对免疫固定电泳结果产生的干扰及消除干扰的方法。方法收集2020年4月至2021年3月北京大学人民医院应用达雷妥尤单抗治疗的8例浆细胞疾病患者的血清样本,分别进行标准的免疫固定电泳检测及Hydrashift 2/4 daratumumab检测。结果达雷妥尤单抗治疗后,81.3%(13/16)的样本出现药物性单克隆条带(IgG-κ型),未出现药物性单克隆条带的样本考虑与个体差异、给药间隔时间、患者免疫球蛋白水平相关。出现IgG-κ型单克隆条带的样本中76.9%(10/13)可通过免疫固定电泳直接分辨为内源性或外源性单克隆条带,余3份样本(3/13)需要使用Hydrashift 2/4 daratumumab检测进行区分。结论应用Hydrashift 2/4 daratumumab检测可去除达雷妥尤单抗对免疫固定电泳结果的干扰,辅助评判疗效。Objective To investigate the interference of daratumumab on immunofixation electrophoresis after treating plasma cell diseases and methods to eliminate the interference.Methods Serum samples of eight patients with plasma cell diseases treated with daratumumab in Peking University People's Hospital from April 2020 to March 2021 were collected for standard immunofixation electrophoresis and Hydrashift 2/4 daratumumab assay.Results After treatment,81.3%(13/16)of the samples showed drug-induced monoclonal antibodies(IgG-κ).The samples without drug-induced monoclonal bands were related to individual differences,administration intervals,and immunoglobulin levels.Among the samples with IgG-κmonoclonal bands,76.9%(10/13)could be directly identified as endogenous or exogenous monoclonal bands by immunofixation electrophoresis,and the others(3/13)could be identified by Hydrashift 2/4 daratumumab assay.Conclusion Hydrashift 2/4 daratumumab assay can remove the band of daratumumab on the immunofixation electrophoresis and help with efficacy evaluation.

关 键 词：达雷妥尤单抗 免疫固定电泳 多发性骨髓瘤 

分 类 号：R733.3[医药卫生—肿瘤]